Regenxbio Inc
RGNX
Get informed when a big investor buys or sells
+ FollowMarket Cap$554.2M
Close$
$25.02
129.3% upside
Current Fair Value
129.3% upsideUndervalued by 129.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $554.20 Million |
|---|---|
| Enterprise Value | $665.49 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.76 |
| Beta | 0.9 |
| Outstanding Shares | 52,820,000 |
Return
| Return on Equity | -273.72% |
|---|---|
| Return on Assets | -50.81% |
| Return on Invested Capital | -53.59% |
Valuation & Multiples
| P/E Ratio | -2.83 |
|---|---|
| PEG | 2.14 |
| Price to Sales | 3.64 |
| Price to Book Ratio | 10.91 |
| Enterprise Value to Revenue | 3.81 |
| Enterprise Value to EBIT | -4.09 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | 2.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$97.63 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.36
Average shareholder expectationRevenue Estimate
$15.88 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6923▲ 1.46% |
|---|---|
| Total Calls | 32,500▼ 92.17% |
| Total Puts | 22,500▼ 92.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 21.01%▼ 61.57% |
|---|---|
| Total Invested | $131.75M▼ 62.90% |
| Investors Holding | 54▼ 135.00% |
ESG Score
No data
About Regenxbio Inc
CEO: Kenneth Mills